Ductal Carcinoma is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Ductal Carcinoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Ductal Carcinoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ductal Carcinoma overview

Ductal Carcinoma is early stage of breast cancer where the ductal cells of the breast tissue tend to multiply or grow uncontrollably without any evidence of metastatic. If not treated in initial stages, this could be invasive. Ductal carcinoma is represented in 4 different stages, pre invasive, non-invasive, ductal intraepithelial neoplasia, intra ductal cancer. In invasive form spread of cancer cells into surrounding tissues is observed. Cause is unknown but mutations in BRCA1 and BRCA2 are believed to be one such cause. Other risk factors are family history, age, HRT, oral contraceptives, alcohol. Mammography is the radiographic method to diagnose ductal carcinoma where screening of breasts is done and tissue biopsy. In most cases it is asymptomatic but, in a few cases, the patients are presented with lump or swelling, pain, and a rash on the nipple. Surgery is the primary option of treatment. Either ductal cells that are cancerous are removed or the whole breast if complications of metastatic or in early stages endocrine therapy.

For a complete picture of PTSR and LoA scores for drugs in Ductal Carcinoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.